Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


QUOTED. April 30, 2019. Bill Edelman.

Executive Summary

Paragonix Technologies is getting ready to market the first US FDA and CE-marked medical device system for transporting donor hearts. See what Paragonix's CEO Bill Edelman said about the company's SherpaPak Cardiac Transport system here:

"[With using the traditional method], the organ is actually compressed between two layers of crushed ice and is sometimes flattened out, and other times the heart muscle itself comes into very direct contact with the ice itself and that can freeze the muscle, so that ice-crystals can form inside the tissue, and that could adversely affect how the muscle recovers after it's been implanted into the recipient." –Bill Edelman, CEO, Paragonix Technologies

Click here for a free trial of Medtech Insight


Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts